JPH0580479B2 - - Google Patents

Info

Publication number
JPH0580479B2
JPH0580479B2 JP61080753A JP8075386A JPH0580479B2 JP H0580479 B2 JPH0580479 B2 JP H0580479B2 JP 61080753 A JP61080753 A JP 61080753A JP 8075386 A JP8075386 A JP 8075386A JP H0580479 B2 JPH0580479 B2 JP H0580479B2
Authority
JP
Japan
Prior art keywords
compound
reaction
derivative
formula
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61080753A
Other languages
Japanese (ja)
Other versions
JPS62238286A (en
Inventor
Kazuo Ogawa
Takatsugu Pponna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP8075386A priority Critical patent/JPS62238286A/en
Publication of JPS62238286A publication Critical patent/JPS62238286A/en
Publication of JPH0580479B2 publication Critical patent/JPH0580479B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

技術分野 本発明は、新規なテトラゾール誘導体に関す
る。 従来技術 本発明のテトラゾール誘導体は、文献未記載の
新規な化合物である。 発明の開示 本発明は、下記一般式
TECHNICAL FIELD The present invention relates to novel tetrazole derivatives. Prior Art The tetrazole derivative of the present invention is a novel compound that has not been described in any literature. DISCLOSURE OF THE INVENTION The present invention is based on the following general formula

【化】 (式中、R1は低級アルキル基を、nは1又は
2の整数を示す。)で表わされるテトラゾール誘
導体に係る。 上記一般式1において、R1で示される低級ア
ルキル基としては、例えばメチル、エチル、プロ
ピル、イソプロピル、ブチル基等の炭素数1〜6
の直鎖又は分枝状のアルキル基を挙げることがで
きる。 本発明化合物は、血糖低下作用、脂質低下作
用、アルドース・リダクターゼ阻害作用等を有
し、糖尿病用剤及び白内障用剤等の医薬として有
用なものである。 本発明に係る前記一般式(1)で表わされるテトラ
ゾール誘導体は、例えば下記反応行程式に示す
様に、一般式(2)で表わされるアルデヒド誘導体と
式(3)で表わされる化合物との反応により製造する
ことができる。 〈反応工程式 〉
It relates to a tetrazole derivative represented by the following formula: (wherein R 1 represents a lower alkyl group, and n represents an integer of 1 or 2). In the above general formula 1, the lower alkyl group represented by R 1 has 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl group, etc.
Mention may be made of straight-chain or branched alkyl groups. The compound of the present invention has a blood sugar lowering effect, a lipid lowering effect, an aldose reductase inhibitory effect, etc., and is useful as a medicine such as a diabetic agent and a cataract agent. The tetrazole derivative represented by the general formula (1) according to the present invention can be obtained by reacting an aldehyde derivative represented by the general formula (2) with a compound represented by the formula (3), for example, as shown in the following reaction scheme. can be manufactured. <Reaction process formula>

【化】[ka]

【化】 (式中、R1,nは前記に同じ。) アルデヒド誘導体(2)は通常のアルドール縮合、
クネベナゲル縮合反応の条件下で化合物(3)と縮合
し、本発明化合物(1)を生成する。これら縮合反応
は著名な反応であり、例えばメルクインデツクス
第10版のオーガニツク ネーム リアクシヨンズ
(Merk Index 10th Edition Organic name
reactions)に記載されている。本縮合に使用さ
れる触媒としては水酸化カリウム、水酸化ナトリ
ウム、水酸化カルシウム、炭酸ナトリウム、炭酸
水素ナトリウム、ナトリアムメトキサイド、ナト
リウムエトキサイド、酢酸ナトリウム等のアルカ
リ金属又はアルカリ土類金属の水酸化物、炭酸
塩、アルコキサイド、その有機酸塩、メチルアミ
ン、エチルアミン、ジエチルアン、トリエチルア
ミン、アニリン、ニコチン、ピリジン、ピペリジ
ン、アンモニア等のアミン類及び無水酢酸、無水
プロピオン酸等の有機無水酸等が用いられる。ア
ルデヒド誘導体(2)と化合物(3)の使用割合は適宜に
選択できるが一般には(2)に対し(3)を1.0〜1.2倍モ
ル程度使用するのが好ましい。反応は通常加熱下
で行われ、一般には溶媒の還流温度において有利
に進行する。溶媒としてはメタノール、エタノー
ル等のアルコール類、ジオキサン等のエーテル類
及び酢酸等が用いられる。 上記反応により生成した本発明のテトラゾール
誘導体は、通常の分離手段、例えば再結晶、カラ
ムクロマトグラフイー等により容易に単離可能で
ある。 本発明は、一般式(1)のいずれの幾何異性体をも
包含する。また、一般式(1)の酸付加塩、アルカリ
金属塩、アルカリ土類金属塩、水和物等も包含す
る。 原料とする一般式(2)で表わされるアルデヒド誘
導体は新規化合物であり、例えば下記反応工程式
に示した方法により製造することが出来る。 〈反応行程式 〉
[Chemical formula] (In the formula, R 1 and n are the same as above.) The aldehyde derivative (2) is a conventional aldol condensation,
It is condensed with compound (3) under the conditions of Knevenagel condensation reaction to produce compound (1) of the present invention. These condensation reactions are well-known reactions, such as those listed in the Organic name reactions of the Merck Index 10th Edition.
reactions). Catalysts used in this condensation include water containing alkali metals or alkaline earth metals such as potassium hydroxide, sodium hydroxide, calcium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide, sodium ethoxide, and sodium acetate. Oxides, carbonates, alkoxides, their organic acid salts, amines such as methylamine, ethylamine, diethylane, triethylamine, aniline, nicotine, pyridine, piperidine, ammonia, and organic anhydrides such as acetic anhydride and propionic anhydride. used. The ratio of aldehyde derivative (2) and compound (3) to be used can be selected as appropriate, but it is generally preferable to use about 1.0 to 1.2 times mole of (3) to (2). The reaction is usually carried out under heating, and generally proceeds advantageously at the reflux temperature of the solvent. As the solvent, alcohols such as methanol and ethanol, ethers such as dioxane, acetic acid, etc. are used. The tetrazole derivative of the present invention produced by the above reaction can be easily isolated by conventional separation means such as recrystallization, column chromatography, etc. The present invention includes any geometric isomer of general formula (1). It also includes acid addition salts, alkali metal salts, alkaline earth metal salts, hydrates, etc. of general formula (1). The aldehyde derivative represented by the general formula (2) used as a raw material is a new compound, and can be produced, for example, by the method shown in the reaction scheme below. <Reaction equation>

【化】[ka]

【化】[ka]

【化】[ka]

【式】 (式中、R1は前記に同じ。R2は低級アルキル
基を意味する。) 即ち、ジエン酸誘導体(4)より例えばアルカノー
ル硫酸によりエステル誘導体(5)とし、これを例え
ばジーイソブチルアルミニウムハンドライドによ
り還元しアルコール誘導体(6)とする。続いて例え
ばクロロクロム酸ピリジニウムにより酸化してジ
エンアルデヒド誘導体(7)を得ることが出来る。 また、原料となる化合物(3)で表わされるテトラ
ゾリルメチルローダニンは新規化合物であり、例
えば下記反応行程式に示した方法により製造す
ることが出来る。 〈反応行程式 〉
[Formula] (In the formula, R 1 is the same as above. R 2 means a lower alkyl group.) That is, the dienoic acid derivative (4) is converted into an ester derivative (5) with, for example, alkanol sulfuric acid, and this is converted into an ester derivative (5), for example, with diisobutyl Reduction with aluminum handlide gives alcohol derivative (6). Subsequently, the dienaldehyde derivative (7) can be obtained by oxidation, for example, with pyridinium chlorochromate. Furthermore, tetrazolylmethylrhodanine, which is represented by compound (3) as a raw material, is a new compound and can be produced, for example, by the method shown in the reaction scheme below. <Reaction equation>

【化】 即ち、テトラゾール誘導体(8)とジチオ酢酸誘導
体(9)をエタノール水中トリエチルアミンの存在下
で加熱還流することによりテトラゾリルメチルロ
ーダニン化合物(3)を得ることが出来る。 次に参考例及び実施例を挙げて本発明を具体的
に説明する。 参考例 1 4−(5−メチルイソキサゾール−3−イル)−
1,3−ペンタジエノイツクアシド2.3gをメタ
ノール100mlと濃硫酸10ml中に加えて8時間加熱
還流した。反応終了後ほとんど溶媒を留去し、残
液に氷水を加えて、析出した結晶を取し、メタ
ノールより再結晶すると融点113〜114℃のメチル
4−(5−メチルイソキサゾール−3−イル)−
1,3−ペンタジエノエイト2.1g(収率84.7%)
を得た。 元素分析(C10H11N1O3として) C H N 計算値(%) 62.17 5.74 7.25 実測値(%) 62.02 6.00 7.18 参考例 2 メチル4−(5−メチルイソキサゾール−3−
イル)−1,3−ペンタジエノエイト2.1gをジク
ロロメタン50mlに溶解し、−70℃以下に冷却下ジ
イソブチルアルミニウムハイドライドの25%トル
エン溶液24mlを滴下した。滴下後−40℃以下で2
時間反応を行ない、10%の水を含むメタノール液
で過剰の還元剤を分解した。有機層は分取し無水
硫酸ナトリウムで乾燥した。乾燥後溶媒を留去し
4−(5−メチルイソキサゾール−3−イル)−
1,3−ペンタジエノール1.3g(収率72.4%)
を得た。 MSスペクトル(m/e):165(M+)。 核磁気共鳴スペクトル(CDCl3)、δ(ppm): 1.95(1H,t)、 2.40(3H,s)、 4.27(2H,t)、 5.70〜6.16(1H,m)、 6.11(1H,s)、 6.20〜6.90(3H,m)。 参考例 3 4−(5−メチルイソキサゾール−3−イル)−
1,3−ペンタジエノール1.2gをジクロロメタ
ン30mlに溶解し、クロロクロム酸ピリジニウム
2.8gを室温下に加えて4時間攪拌した。反応後、
有機層を分取し、濃縮した。残渣をカラムクロマ
トグラフイー(展開溶媒はクロロホルム)にて精
製し、融点134〜135℃の4−(5−メチルイソキ
サゾール−3−イル)−1,3−ペンタジエナー
ル0.35g(収率29.5%)を得た。 元素分析(C9H9N1O2として) C H N 計算値(%) 66.25 5.56 8.58 実測値(%) 65.90 5.31 8.51 参考例 4 アミノメチルテトラゾール(化合物(8))5gを
水50mlとエタノール100mlの混液中に加えトリエ
チルアミン7mlを滴下し溶解させた。続いてカル
ボキシメチルトリチオカルボネイト(化合物(9))
11.3gを加えて4時間加熱還流した。反応冷却後
析出物を取し、水より再結晶すると融点173℃
の3−(テトラゾール−5−イル)メチルローダ
ニン(化合物(3))8g(収率73.7%)を得た。 元素分析(C5H5N5OS2として) C H N 計算値(%) 27.90 2.34 32.53 実測値(%) 28.25 2.25 32.56 実施例 1 3−メチル−イソキサゾール−5−アクリルア
ルデヒド0.25g、3−(テトラゾール−5−イル)
メチルローダニン0.6g、無水の酢酸ナトリウム
0.2gを酢酸7ml中に加えて、更に無水酢酸0.3ml
を添加し1時間加熱攪拌した。反応後析出物を濾
取し、酢酸より再結晶を行い融点265〜266℃(分
解)の5−〔(3−メチル−5−イソキサゾール)
−1,3−プロパンジエン〕−3−(5−テトラゾ
リルメチル)ローダニン(化合物1)の0.28g
(収率45.6%)を得た。 実施例 2 実施例1と同様な方法にて第1表に示す化合物
2〜3を合成した。
embedded image That is, the tetrazolylmethylrhodanine compound (3) can be obtained by heating and refluxing the tetrazole derivative (8) and the dithioacetic acid derivative (9) in ethanol water in the presence of triethylamine. Next, the present invention will be specifically explained with reference to reference examples and examples. Reference example 1 4-(5-methylisoxazol-3-yl)-
2.3 g of 1,3-pentadienoic acid was added to 100 ml of methanol and 10 ml of concentrated sulfuric acid, and the mixture was heated under reflux for 8 hours. After the reaction, most of the solvent was distilled off, ice water was added to the residual liquid, the precipitated crystals were collected, and recrystallized from methanol to give methyl 4-(5-methylisoxazol-3-yl) with a melting point of 113-114°C. )−
1,3-pentadienoate 2.1g (yield 84.7%)
I got it. Elemental analysis (as C 10 H 11 N 1 O 3 ) C H N Calculated value (%) 62.17 5.74 7.25 Actual value (%) 62.02 6.00 7.18 Reference example 2 Methyl 4-(5-methylisoxazole-3-
2.1 g of diisobutylaluminum hydride (2.1 g)-1,3-pentadienoate was dissolved in 50 ml of dichloromethane, and 24 ml of a 25% toluene solution of diisobutylaluminum hydride was added dropwise while cooling to below -70°C. 2 below -40℃ after dropping
The reaction was carried out for a period of time, and the excess reducing agent was decomposed with a methanol solution containing 10% water. The organic layer was separated and dried over anhydrous sodium sulfate. After drying, the solvent was distilled off to give 4-(5-methylisoxazol-3-yl)-
1,3-pentadienol 1.3g (yield 72.4%)
I got it. MS spectrum (m/e): 165 (M + ). Nuclear magnetic resonance spectrum ( CDCl3 ), δ (ppm): 1.95 (1H, t), 2.40 (3H, s), 4.27 (2H, t), 5.70-6.16 (1H, m), 6.11 (1H, s) , 6.20-6.90 (3H, m). Reference example 3 4-(5-methylisoxazol-3-yl)-
Dissolve 1.2 g of 1,3-pentadienol in 30 ml of dichloromethane and add pyridinium chlorochromate.
2.8 g was added at room temperature and stirred for 4 hours. After the reaction,
The organic layer was separated and concentrated. The residue was purified by column chromatography (developing solvent was chloroform) to obtain 0.35 g of 4-(5-methylisoxazol-3-yl)-1,3-pentadienal with a melting point of 134-135°C (yield: 29.5%). Elemental analysis (as C 9 H 9 N 1 O 2 ) C H N Calculated value (%) 66.25 5.56 8.58 Actual value (%) 65.90 5.31 8.51 Reference example 4 5 g of aminomethyltetrazole (compound (8)) was mixed with 50 ml of water and ethanol Into 100 ml of the mixed solution, 7 ml of triethylamine was added dropwise and dissolved. Then carboxymethyl trithiocarbonate (compound (9))
11.3 g was added and heated under reflux for 4 hours. After cooling the reaction, remove the precipitate and recrystallize it from water to obtain a melting point of 173°C.
8 g (yield 73.7%) of 3-(tetrazol-5-yl)methylrhodanine (compound (3)) was obtained. Elemental analysis (as C 5 H 5 N 5 OS 2 ) C H N Calculated value (%) 27.90 2.34 32.53 Actual value (%) 28.25 2.25 32.56 Example 1 3-Methyl-isoxazole-5-acrylaldehyde 0.25 g, 3- (tetrazol-5-yl)
Methylrhodanine 0.6g, anhydrous sodium acetate
Add 0.2g to 7ml of acetic acid, then add 0.3ml of acetic anhydride.
was added, and the mixture was heated and stirred for 1 hour. After the reaction, the precipitate was collected by filtration and recrystallized from acetic acid to obtain 5-[(3-methyl-5-isoxazole) with a melting point of 265-266°C (decomposition).
-1,3-propanediene]-3-(5-tetrazolylmethyl)rhodanine (compound 1) 0.28 g
(yield 45.6%). Example 2 Compounds 2 and 3 shown in Table 1 were synthesized in the same manner as in Example 1.

【表】【table】

Claims (1)

【特許請求の範囲】 1 一般式 【化】 (式中、R1は低級アルキル基を、nは1又は
2を示す。)で表わされるテトラゾーン誘導体。
[Claims] 1. A tetrazone derivative represented by the general formula: (wherein R 1 represents a lower alkyl group, and n represents 1 or 2).
JP8075386A 1986-04-08 1986-04-08 Tetrazole derivative Granted JPS62238286A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8075386A JPS62238286A (en) 1986-04-08 1986-04-08 Tetrazole derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8075386A JPS62238286A (en) 1986-04-08 1986-04-08 Tetrazole derivative

Publications (2)

Publication Number Publication Date
JPS62238286A JPS62238286A (en) 1987-10-19
JPH0580479B2 true JPH0580479B2 (en) 1993-11-09

Family

ID=13727165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8075386A Granted JPS62238286A (en) 1986-04-08 1986-04-08 Tetrazole derivative

Country Status (1)

Country Link
JP (1) JPS62238286A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2835545B2 (en) * 1990-11-27 1998-12-14 株式会社大塚製薬工場 Cataract prevention and treatment agent
JP2835547B2 (en) * 1991-12-25 1998-12-14 株式会社大塚製薬工場 Diabetes treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430171A (en) * 1977-08-10 1979-03-06 Taiho Pharmaceutical Co Ltd Isooxazole derivative and production
JPS6127984A (en) * 1984-07-16 1986-02-07 Taiho Yakuhin Kogyo Kk Phodanineacetic acid derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430171A (en) * 1977-08-10 1979-03-06 Taiho Pharmaceutical Co Ltd Isooxazole derivative and production
JPS6127984A (en) * 1984-07-16 1986-02-07 Taiho Yakuhin Kogyo Kk Phodanineacetic acid derivative

Also Published As

Publication number Publication date
JPS62238286A (en) 1987-10-19

Similar Documents

Publication Publication Date Title
JPH0257546B2 (en)
JPS6242903B2 (en)
EP0550313A1 (en) 2-(Tetranol-5-yl)-(1,1&#39;-biphenyl)derivatives, their preparation and use as intermediates
CA2676072C (en) Process for the preparation of 2-substituted 5-(1-alkylthio) alkylpyridines
JPS6212776A (en) Rhodanine derivative
JPH01156965A (en) Thiohydantoin compound
JPH0580479B2 (en)
JP3564982B2 (en) 4-Fluoro-3-oxocarboxylic acid ester and method for producing the same
JP2511335B2 (en) Production method of 2,2-dimethyl-5- (2,5-dimethylphenoxy) pentanoic acid, production intermediate thereof, and production intermediate
JP3259191B2 (en) Synthesis of 2,2&#39;-anhydroarabinosyl thymine derivatives
JPS6126556B2 (en)
JP2519471B2 (en) Rhodanine compound
KR890001241B1 (en) Process for preparing 4-acetyl isoquinolinone
US5508446A (en) Method for producing alkyl 3-phthalidylideneacetate
JPS6259707B2 (en)
JPS584698B2 (en) Method for producing 2-(3-benzoylphenyl)propionic acid
JP4110633B2 (en) 3-Amino-4-fluoro-2-unsaturated carboxylic acid ester and process for producing the same
JPS61246176A (en) Preparation of aminolactone
JPH0576473B2 (en)
JPH0348909B2 (en)
KR840000961B1 (en) Process for the preparation of cyclic carboxylic acid derivative
JPH0129793B2 (en)
KR790000808B1 (en) Thiazole derivatives and the production there of
JP4356917B2 (en) Process for producing bisaminomethyl-1,4-dithianes and intermediates thereof
JPH0588693B2 (en)